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Factor XII (FXII) deficiency, which is also known as Hageman factor deficiency, was first described in the medical literature by Dr. Oscar Ratnoff and Dr. Jane Colopy, 
in 1955, in a patient named John Hageman. The precise incidence 
of the disorder in the common population is still unknown, but it 
is found approximately 1 in 1 million individuals [1]. It is more 
common in Asians than other ethnic groups. FXII deficiency is 
inherited in an autosomal recessive fashion [2], but autosomal 
dominant inheritance was also reported [3]. Soria et al. [4] 
conducted a genome-wide linkage screen to confine genes that 
influenced the variation in levels of FXII. Two genetic loci 
were detected on chromosome 5 and 10. Hereditary coagulation 
FXII deficiency is also identified in a patient with heterozygous 
missense mutation at exon 13 of FXII gene [5].
FXII is a beta-globulin serine protease (single chained) with a 
molecular weight of 80,000-84,000 Da and a plasma concentration 
of 30 pg/mL, respectively. Proteolytic cleavage of FXII is mediated 
by charged surfaces (kaolin, glass, dextran sulfate, cellulite, 
endotoxin, crude collagen, urates, and sulfatides), kallikrein, 
and autoactivation. Prekallikrein, FVII, FXI, complement C1, 
and plasminogen are cleaved by activated FXII proteolytically 
(FXIIa) into their active forms [6]. FXIIa plays a dual role in the 
cascade reactions of coagulation. It can stimulate FXI, which, in 
turn, activates FIX (previous intrinsic pathway); however, this 
is its marginal function. The major function is the conversion 
of plasminogen into plasmin which takes place with the help of 
activated FXII and initiation of fibrinolysis. In the human body, 
processes of fibrinolysis and coagulation are constantly in a 
dynamic equilibrium; therefore, factor deficiency can potentially 
increase the risk of thrombosis [7].
In a non-bleeding child or adult, congenital FXII deficiency 
is the familiar cause of an isolated prolongation of activated 
partial thromboplastin time (aPTT). Most patients are detected 
during a routine pre-operative coagulation study [8]. Most of 
the patients resist severe challenges to the hemostatic system, 
such as major surgery or dental extractions without bleeding; 
although, epistaxis or easy bruising has been reported in FXII 
deficient patient occasionally. In contrast to the usual lack of 
bleeding manifestations, there is an increased incidence of serious 
thromboembolic problems in patients with hereditary FXII 
deficiency. The first patient discovered to have FXII deficiency, 
John Hageman, died of a pulmonary embolus [9].
CASE REPORT
A 7-month-old 2nd born male child was born to a non-consanguineously 
married Indian couple at term by normal vaginal delivery with birth 
weight of 2.6 kg. At the age of 4 months, he developed multiple 
ecchymotic patches all over the body. These ecchymotic patches 
were self-resolving in nature and reappeared in every 10-15 days. 
History of prolong bleeding after minor trauma was present. There 
was no history of any bleeding disorder in any other family member. 
The child was exclusively breastfed till the age of 3 months, and 
thereafter, weaning started with buffalo milk and biscuits.
On physical examination, multiple ecchymotic patches were 
present over the trunk, back, arms, and legs, largest measuring 
3 cm × 2.5 cm (Fig. 1a and b). Except undernutrition: Weight 
6.8 kg  (−2SD  to −3SD), growth, and development were within 
normal limits (occipitofrontal circumference 44 cm [between 
−1SD and +1SD],  length 65.5 cm [between −2SD and −1SD]). 
Systemic examination was normal.
On blood investigation, complete blood count revealed 
microcytic hypochromic anemia (hemoglobin 9.7 g/dL). Platelet 
count was 547,000/mm3. Renal and liver function tests were 
within normal limits. During the hospital stay, the patient was 
given vitamin K and supportive treatment. Documented evidence 
of persistent elevation of aPTT at our center is listed in Table 1. 
To find out the cause of excessively raised level of aPTT, 
investigation to measure the concentration of clotting factor was 
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sent which revealed following parameters as listed in Table 2.
We found the low level of FXII in this case, which is a 
rare disorder; so we are reporting this case. Since the child 
showed no evidence of gross bleeding during his hospital stay, 
so vitamin K was stopped and discharged on iron-folic acid, 
calcium, and vitamin D drops. The patient has been advised for 
regular follow-up at our center (at least every 3 months). The 
possibility of occurrence of thromboembolic complications has 
been explained to the parents.
DISCUSSION
Deficiency of coagulation FXII is either acquired or congenital. 
Acquired FXII deficiency is found in patients who has nephrotic 
syndrome. The pathological basis of this deficiency has not 
been recognized since the urinary loss of FXII is not only the 
cause for the reduced plasma activity. Other causes of acquired 
FXII deficiency are liver transplantation, autoimmune diseases, 
in association with von Willebrand disease, FVIII or FIX 
deficiency, high molecular weight kininogen deficiency, heparin 
contamination, liver diseases, prekallikrein deficiency, and lupus 
anticoagulants [10].
Another kind of coagulation deficiency is congenital 
coagulation FXII deficiency which is a rare autosomal recessive 
hereditary disease. Its manifestations are low factor concentration 
without significant bleeding. As a result, deficiency of coagulation 
FXII is often diagnosed by regular coagulation tests conducted 
before surgeries. Since no severe bleeding occurs, there is not any 
requirement of specific treatment [11].
There have been lots of reports of association of Hageman 
factor deficiency of myocardial infarction (MI), and recurrent 
pregnancy losses. Therefore, on detection of Hageman factor 
deficiency, clinician must think about these associated risks 
in female patients rather than internal or visible bleeding. The 
patient of low Hageman factor can die due to acute MI and 
pulmonary embolism. So, better risk management is must for the 
better prognosis of individuals affected with FXII deficiency.
There should not be any unnecessary delay in surgical 
interventions and investigations that are not needed in patients 
of isolated FXII deficiency. In recent years, it is found that 
fibrinolytic effect of FXII is more important than its role in 
intrinsic coagulation pathway. Currently, researchers are more 
concerned on thrombotic complications (cardiovascular and 
cerebrovascular) in FXII deficiency patients [10]. As most of the 
patients detected with FXII deficiency are asymptomatic, so no 
treatment may be needed.
CONCLUSION
FXII deficiency is associated with isolated prolonged aPTT 
without the risk of bleeding, so it is important to recognize 
deficiency of FXII in all cases of isolated prolonged aPTT to 
prevent unnecessary fresh frozen plasma transfusions. The delay 
in surgical interventions due to fear of bleeding and unnecessary 
investigations are not needed in patients of isolated FXII 
deficiency. Furthermore, these patients should be at followed up 
regularly due to the increased risk of thromboembolic episodes.
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Table 1: aPTT and clotting time during patient’s stay
Date of investigation aPTT Clotting time
02-04-2016 89.5 s >15 min
12-04-2016 68.5 s >15 min
aPTT: Activated partial thromboplastin time
Table 2: Measurement of clotting factor in percentage
Clotting factor Percentage detected Normal limits (%)
VIII 86.0 56-191
IX 95.0 36-136
XII 40.4 70-120
Funding: None; Conflict of Interest: None Stated.
How to cite this article: Kumar R, Gupta A, Mathur P, Garg M. Factor 
XII deficiency - A rare coagulation disorder. Indian J Child Health. 2016; 
3(4):349-350.
Figure 1: (a and b) Ecchymotic patches over back of arm and flexor 
aspect of forearm
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